Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 2Multiple Myeloma 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × lucatumumab × Clear all
NCT00670592 2020-12-17

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Novartis

Phase 1/2 Completed
111 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT01275209 2020-12-08

LIFT

Novartis

Phase 1 Completed
1 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00231166 2018-10-11

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

Novartis

Phase 1 Completed
33 enrolled
Plasma cell

Multiple Myeloma

NCT00108108 2012-10-01

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Novartis

Phase 1 Terminated
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡